Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04995484 · ClinicalTrials.gov registry record · Phase 1

A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)

A Phase 1 study of Moderate Hepatic Impairment, sponsored by Merck Sharp & Dohme.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target
2
Study locations

NCT04995484 is a Phase 1 study of Moderate Hepatic Impairment that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 17 participants, below the 21-participant average among 4 other Moderate Hepatic Impairment trials with a reported enrollment target (19% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04995484, a Phase 1 study of Moderate Hepatic Impairment, has completed, sponsored by Merck Sharp & Dohme.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target
2
Study locations

Study Summary

The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment to that of healthy matched control participants. This study will also evaluate the safety and tolerability of a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment.

Conditions Studied

Moderate Hepatic Impairment

Interventions

  • DRUG Belzutifan

Study Locations (2)

Florida

  • Orlando Clinical Research Center ( Site 0001) - Orlando

Texas

  • The Texas Liver Institute ( Site 0002) - San Antonio

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2022-06-24
Est. Completion 2024-01-03
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04995484

The ClinicalTrials.gov registry entry for NCT04995484 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 21-participant average among 4 other Moderate Hepatic Impairment trials with a reported enrollment target (19% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Moderate Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which Belzutifan is the first listed.

NCT04995484 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT04995484 about?

NCT04995484 is a clinical study titled "A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)". The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment to that of healthy matched control participants. This study will also evaluate the safety and tol...

What is the current status of trial NCT04995484?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2022-06-24. Estimated completion is 2024-01-03.

What conditions does trial NCT04995484 study?

This clinical trial studies the following conditions: Moderate Hepatic Impairment.

What interventions are being tested in trial NCT04995484?

The interventions under investigation include: Belzutifan (DRUG).

Who is sponsoring clinical trial NCT04995484?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04995484 being conducted?

This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Moderate Hepatic Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Moderate Hepatic Impairment

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.